A new publication involving icatibant appeared on August 21, 2026. The article, titled "Real-World Safety and Effectiveness of Icatibant in Patients With Hereditary Angioedema (HAE): Post-Marketing Surveillance in Japan," was published in The Journal of Dermatology.
The publication is identified as post-marketing surveillance research conducted in Japan, focused on patients with hereditary angioedema, or HAE. According to the listed details, the study addresses real-world safety and effectiveness data collected after icatibant's marketing approval.
No specific findings, results, or outcome data were provided alongside this publication record. This brief reports only that the publication exists, its title, its journal, and its listed date. Readers seeking the specific safety or effectiveness data reported in the study should consult the original article directly through the journal.
Icatibant remains an approved compound. This publication record does not itself state or imply any particular safety concern or benefit beyond confirming that the study was published. Interested readers can review the compound overview for additional background and context on icatibant.